Patents by Inventor Lorenzo Codan

Lorenzo Codan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline forms of 1-[(3R,4S)-4-cyanotetrahydropyran-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridyl)amino]pyrazole-4-carboxamide
    Patent number: 12018020
    Abstract: The present application relates to crystalline forms of 1-[(3R,4S)-4-cyanotetrahydropyran-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridyl) amino]pyrazole-4-carboxamide and processes for the preparation thereof. The compound is useful for the treatment of JAK-mediated diseases or conditions such as atopic dermatitis.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: June 25, 2024
    Assignee: Intervet Inc.
    Inventors: Christophe Pierre Alain Chassaing, Xiaoling Jin, Rositza Iordanova Petrova, Richard J. Varsolona, Lorenzo Codan, Edward Cleator, Adrian Goodyear, Jonathan Simmons, Tanja Schweisel
  • PROCESS FOR PREPARING SUGAMMADEX
    Publication number: 20230312887
    Abstract: The present invention relates to a process for drying crystalline sugammadex to meet solvent specifications that is independent of API crystallinity or crystalline form generated. It further relates to use of sugammadex in the reversal of neuromuscular blockade induced by recuronium bromide or by vecuronium bromide in adults undergoing surgery.
    Type: Application
    Filed: September 8, 2021
    Publication date: October 5, 2023
    Applicants: Merck Sharp & Dohme LLC, Werthenstein BioPharma GMBH
    Inventors: David J. Lamberto, Paolo Avalle, Lorenzo Codan, Patrick Larpent, Jochen Schoell, Jeffrey S. Neuhaus
  • NOVEL CRYSTALLINE FORMS OF SUGAMMADEX
    Publication number: 20220049023
    Abstract: The present invention provides a novel crystalline forms of sugammadex, designated herein as crystalline form Type 1 of sugammadex, crystalline form Type 2 of sugammadex, crystalline form Type 3 of sugammadex, crystalline form Type 8 of sugammadex, and crystalline form Type 9 of sugammadex, pharmaceutical compositions thereof, and methods for their use in the reversal of neuromuscular blockade induced by recuronium bromide or by vecuronium bromide in adults undergoing surgery.
    Type: Application
    Filed: September 25, 2019
    Publication date: February 17, 2022
    Applicant: Werthenstein Biopharma GMBH
    Inventors: Paolo Avalle, Lorenzo Codan, Patrick Larpent, Jochen Scholl
  • Crystalline Forms of 1-[(3R,4S)-4-Cyanotetrahydropyran-3-YL]-3-[(2-Fluoro-6-Methoxy-4-Pyridyl)Amino]Pyrazole-4-Carboxamide
    Publication number: 20220024902
    Abstract: The present application relates to crystalline forms of 1-[(3R,4S)-4-cyanotetrahydropyran-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridyl) amino]pyrazole-4-carboxamide and processes for the preparation thereof. The compound is useful for the treatment of JAK-mediated diseases or conditions such as atopic dermatitis.
    Type: Application
    Filed: December 12, 2019
    Publication date: January 27, 2022
    Applicant: Intervet Inc.
    Inventors: Christophe Pierre Alain Chassaing, Xiaoling Jin, Rositza Iordanova Petrova, Richard J. Varsolona, Lorenzo Codan, Edward Cleator, Adrian Goodyear, Jonathan Simmons, Tanja Schweisel